{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:04:09Z","timestamp":1790345049723,"version":"4.1.0"},"reference-count":6,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2026,9,9]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1136\/egastro-2026-100619","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:17Z","timestamp":1790343917000},"page":"e100619","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?"],"prefix":"10.1136","volume":"4","author":[{"given":"Xiao-Dong","family":"Zhou","sequence":"first","affiliation":[{"name":"MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"},{"name":"Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[{"name":"Summit Clinical Research, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Muthiah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[{"name":"MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"},{"name":"Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092506450951000_4.3.e100619.1","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2026-100369","article-title":"Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023","volume":"4","author":"Zhou","year":"2026","journal-title":"eGastroenterology"},{"key":"2026092506450951000_4.3.e100619.2","doi-asserted-by":"crossref","unstructured":"Fallowfield JA , Ramachandran P , Kendall TJ . Regression of liver cirrhosis. J Hepatol 2026. doi:10.1016\/j.jhep.2026.05.026","DOI":"10.1016\/j.jhep.2026.05.026"},{"key":"2026092506450951000_4.3.e100619.3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2468-1253(26)00123-8","article-title":"Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial","volume":"11","author":"Loomba","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092506450951000_4.3.e100619.4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092506450951000_4.3.e100619.5","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.cmet.2026.03.011","article-title":"The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors","volume":"38","author":"Gonzalez-Rellan","year":"2026","journal-title":"Cell Metab"},{"key":"2026092506450951000_4.3.e100619.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-337431"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2026-100619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:19Z","timestamp":1790343919000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2026-100619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":6,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/egastro-2026-100619"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2026-100619","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}